New aims and next steps for adult ALL induction therapy
How can plasma cell leukemia be managed?
The epigenetics of multiple myeloma and the rationale for HDAC inhibitors
Comparing continuous and fixed duration myeloma treatment with triplets and doublets
Management of transplant-eligible myeloma patients in 2017